As of close of business last night, Iovance Biotherapeutics Inc’s stock clocked out at $11.89, down -3.80% from its previous closing price of $12.36. On the day, 6378704 shares were traded.
Ratios:
To gain a deeper understanding of IOVA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Buy rating and assigned the stock a target price of $12.
On September 18, 2023, Barclays reiterated its Overweight rating and also upped its target price recommendation from $40 to $18.
Wells Fargo Upgraded its Equal Weight to Overweight on May 30, 2023, whereas the target price for the stock was revised from $11 to $17.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 20 ’24 when Rothbaum Wayne P. bought 5,000,000 shares for $9.15 per share. The transaction valued at 45,750,000 led to the insider holds 28,067,333 shares of the business.
MCPEAK MERRILL A bought 250,000 shares of IOVA for $2,287,500 on Feb 20 ’24. The Director now owns 320,150 shares after completing the transaction at $9.15 per share. On Feb 20 ’24, another insider, Dukes Iain D., who serves as the Director of the company, bought 32,000 shares for $9.15 each. As a result, the insider paid 292,800 and bolstered with 54,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2790.75 while its Price-to-Book (P/B) ratio in mrq is 5.21.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $3.21.
Shares Statistics:
A total of 256.14M shares are outstanding, with a floating share count of 220.07M. Insiders hold about 21.21% of the company’s shares, while institutions hold 67.23% stake in the company.
Earnings Estimates
As of right now, Iovance Biotherapeutics, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $4.10, with high estimates of $10.99 and low estimates of $14.40.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Technology.
